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Abstract
We showed the present data about the efficacy and safety of inhaled short-acting b2-agonists (SABA), such as salbutamol and 
fenoterol, in the management of obstructive diseases in children and adults. Our work discusses major mechanisms of action, 
clinical effects, possible side effects and indications of inhaled SABA. We presented current recommendations for the position 
of SABA in the therapy of obstructive diseases in children and adults, particularly in asthma and chronic obstructive pulmonary 
disease.
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Introduction
Short-acting b2-agonists (SABA) stimulate 
b2-adrenergic receptor (b2-AR). They are called 
b2-mimetics or b2-agonists. First selective SABA 
widely used in clinical practice appeared more 
than 50 years ago. They were introduced to the 
global market in the following order: terbutaline 
(1966 yr.), salbutamol (1968 yr.) and fenoterol 
(1970 yr.) [1]. Next drugs, such as levalbuterol, 
reproterol, rimiterol, klenbuterol and pirbuterol, 
were introduced afterwards  [2–4]. Short-act-
ing b2-agonists are selective agonists of b2-AR, 
however they differ in their degree of selectivity. 
Salbutamol (albuterol) is the most used SABA 
in the world — in US it took 9th place on the list 
of prescribed medicines in 2016 (70 million of 
prescriptions) [5]. According to World Health 
Organization (WHO) salbutamol ranks among the 
most effective and safest medicines essential to 
health care systems [6]. Racemic salbutamol is an 
equal (1:1) mixture of R-salbutamol (levalbuterol) 
and S-salbutamol isomers. R-isomer of salbutamol 
is a pharmacologically active compound which 
exhibits many clinical effects, including potent 
bronchodilation [7]. Suppression of bronchoc-
onstriction and bronchodilation occur 5 minutes 
after administration of inhaled salbutamol, but 
the duration of action does not exceed 4–6 hours 
(Figure 1) [8].
Drugs from this group provide effective 
protection against exercise-induced bronchoc-
onstriction within 0.5–2.0 hours also against 
bronchoconstriction triggered by exposure to 
sensitizing allergen [9, 10]. Clinical studies show 
more potent bronchodilation and less side effects 
of R-salbutamol in comparison with racemic sal-
butamol [11–13]. High cost of levalbuterol justi-
fies, however, its administration only in selected 
clinical conditions [13].
Salbutamol versus fenoterol
Two inhaled drugs from SABA group are 
available in Poland: salbutamol and fenoterol. 
Table 1 shows their most important properties.
Data in the table demonstrate that b2/b1 (se-
lectivity index) stimulation index is 10 times 
greater for salbutamol than fenoterol. Having 
in mind similar stimulation of b2 receptors by 
both drugs (0.55 salbutamol vs 0.60 fenoterol), 
it means that salbutamol exerts more selective 
b2-AR stimulation vs fenoterol and both cause 
similar bronchodilation. Studies from the 1990s 
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proved similar or better clinical efficacy and 
better safety of salbutamol in comparison with 
inhaled fenoterol in different age groups of asth-
ma patients [16, 17]. Better safety is also a result 
of the fact that salbutamol shows more features 
of b2-AR partial agonist than fenoterol. It deter-
mines that asthma patients using salbutamol 
have lower risk of death vs patients using feno-
terol [17, 18]. It should be stressed that adverse 
effects of fenoterol increase in hypoxemia, which 
occurs during severe and prolonged episode of 
bronchoconstriction [19].
Clinical effects of SABA
Short-acting b2-agonists in conditions with 
bronchoconstriction exert many following clini-
cal effects [1, 15]:
— bronchodilation (removal of bronchial 
smooth muscles constriction);
— prevention of bronchoconstriction induced 
by different bronchoconstrictive factors;
— reduction of capillary permeability (reduc-
tion of plasma exudate);
— suppression of sensory nerves activation;
— improvement of mucociliary clearance;
— dilatation of pulmonary vascular bed (de-
crease in pO2);
— increased release of surfactant.
They can depend on the polymorphism of 
gene encoding b2-AR located on chromosome 
5q31-q32 [20, 21]. Some studies showed rela-
tionship between response to SABA, course of 
asthma and the polymorphism of gene encoding 
b2-AR [22]. It is mainly about 2 polymorphisms: 
genotype Arg/Arg at codon 16 of gene encoding 
b2-AR and Gln/Gln at codon 27 of this gene. It 
was revealed that homozygotes for Arg/Arg at 
codon 16 of gene encoding b2-AR with chronic 
obstructive pulmonary disease (COPD) are pre-
disposed to more severe clinical course of the 
disease [23]. Similar relationship was shown in 
patients with cystic fibrosis with altered response 
to SABA [24].
Figure 1. Effect of single dose of salbutamol, formoterol, and salmeterol on FEV1 value in asthma patients [8]. 
FEV1 — forced expiratory volume in the first second
Table 1. Comparison of short-acting b2-agonists’ (salbutamol and fenoterol vs isoproterenol) ability to stimulate b-adrener-
gic receptors ( b1, b2, b3) [14, 15]
b1 inotropic activity 
(atrium)
b2 dilatory activity (bron-
chi)*
b3 lipolytic activity (adi-
pocytes)
b2/b1 index
Isoproterenol 1,0 1,0 1,0 1,0
Salbutamol 0,0004 0,55 0,002 1375
Fenoterol 0,005 0,6 0,02 120
*Increase in FEV1 (forced expiratory volume in the first second) ≥ 15% from baseline
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Short-acting b2-agonists usage can be associ-
ated with many side effects described may years 
ago [25]: tachycardia, skeletal muscle tremor, 
hypokalaemia, increased level of lactic acid in 
plasma (lactic acidosis), headaches, hypergly-
caemia. Systemic side effects are observed rarely 
after inhalation administration and increased risk 
of cardiovascular side effects appear in patients 
with comorbid cardiovascular disease, especially 
in the elderly [26, 27]. It is worth mentioning 
that paradoxical bronchoconstriction after in-
halation of SABA occurs in 4.4% of the general 
population [28].
There are additional possible side effects and 
adverse clinical effects when SABA are used in 
asthma. These effects occur in patients receiving 
SABA as monotherapy or/and if SABA are used 
very often or regularly without inhaled cortico-
steroids (ICS). It can lead to increased risk of the 
following adverse outcomes [29–35]:
— decrease in the number and sensitivity of 
b2-AR;
— diminished bronchial response to SABA or/ 
/and LABA;
— increased bronchial hyperresponsiveness;
— increased allergic reactions and eosinophilic 
airway inflammation;
— increased risk for asthma exacerbation (with 
regular or frequent use: ≥ 3 SABA canisters/ 
/year, average 1.7 puffs/day);
— increased risk of death in patients with asth-
ma (≥ 11 SABA canisters/year);
— deterioration in spirometric parameters.
These facts which are known for many years 
and other new clinical evidences for efficacy and 
safety of SMART therapy (Single Maintenance 
and Reliver Therapy) changed the perception of 
the role and place of SABA in the management 
of asthma in last Global Initiative for Asthma 
report (GINA) 2019 [36], which will be discussed 
further below. Another way of limiting the SABA 
overuse relies on monitoring use of SABA by 
patients preferably with electronic inhalers [37, 
38], including inhalers transmitting information 
to the health care system in real time [39].
Salbutamol in pressurised metered-dose 
inhaler in comparison to other pharmaceutical 
forms of SABA
Short-acting b2-agonists have different routes 
of administration (inhalation, oral and intrave-
nous), because they are available in different 
pharmaceutical forms. Many forms of salbutamol 
are available [40]:
— inhalation aerosol (suspension) from pres-
surised metered-dose inhaler (pMDI) (chil-
dren and adults);
— powder from dry powder inhaler (DPI), types: 
Diskus (children over 4 years and adults), 
Turbuhaler (children over 3 years and adults) 
and Easyhaler and (children over 4 years, 
adults);
— inhalation solution for nebulizers (children 
and adults);
— sirup (children over 2 years, adults);
— tablets (children over 2 years, adults);
— solution for injection (adults).
Inhalation is the most effective way of SABA 
therapy in airway diseases. Oral therapy can be 
alternative only exceptionally in small children, 
who do not accept inhalation or cannot inhale 
properly [38]. Additional parenteral therapy 
(salbutamol) is necessary rarely in patients with 
severe exacerbation of asthma, who do not re-
spond do proper inhalation therapy [41].
Inhalation formulations of SABA most often 
used are listed in Table 2 [43].
According to table 2, four inhalation formu-
lations of salbutamol are available: pMDI, pres-
surised metered-dose inhaler — breath actuated 
pMDI (pMDI-BA), DPI and inhalation solution 
for nebulizers; fenoterol is available only as 
pMDI. The expected therapeutic clinical effects 
and probability of side effects can depend on 
the choice of SABA inhalation method. Below 
we present the most important rules of SABA 
inhalation therapy:
Table 2. Inhalation formulations of SABA and SABA/ipratropium bromide combinations. Abbreviations according to [44]
Type of inhaler pMDI pMDI-BA MDLI (respimat) DPI Nebulization
Salbutamol + + – + +
Fenoterol + – – – –
Salbutamol + ipratropium bromide +* – + – +
Fenoterol + ipratropium bromide + – + – +
pMDI — pressurised metered-dose inhaler; pMDI-BA — pressurised metered-dose inhaler — breath actuated); MDLI — metered dose liquid inhaler; DPI — dry 
powder inhaler
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1. pMDI with properly fitted inhalation cham-
ber is preferred method of SABA inhalation 
in children below 6 years, irrespective of 
severity of asthma attack, place of adminis-
tration (home, admission ward, clinical ward, 
intensive care unit) [36, 45, 46].
2. Dose of salbutamol from pMDI depends main-
ly on the severity of asthma attack, not on 
patient age. According to GINA 2019 report 
during the first hour children below 6 years 
can receive up to 6 puffs, older children and 
adults can receive up to 12–30 puffs [36].
3. Salbutamol can be inhaled from DPI (e.g: 
Diskus and Easyhaler) in children above 
6 years and adult with asthma, which pro-
vides similar clinical efficacy to pMDI [36]. 
Studies on administration of salbutamol from 
other DPI are ongoing [47].
4. Nebulization with pneumatic nebulizer — both 
intermittent and continuous — should be used 
in case of insufficient response or lack of re-
sponse to SABA and life-threatening bronchoc-
onstriction [36, 48, 49]. In adults with severe 
exacerbation of asthma continuous nebulized 
salbutamol more effectively improves lung 
function than intermittent nebulization [50].
5. Clinical effects of salbutamol nebulization to 
a considerable degree depend on the type of 
nebulizer: breath actuated pneumatic nebu-
lizer provides better effect than continuous 
nebulization and mesh nebulizer in compar-
ison to pneumatic nebulizer [51, 52].
Table 3. Current indications for SABA in children and adults [36, 55–64]*
Disease/state Indications Comment
Asthma Attacks of dyspnoea, cough, and wheeze
Disease exacerbations
Prevention of exercise-induced 
bronchoconstriction
Prevention of bronchoconstriction triggered 
by allergen exposure 
Alternative to SMART therapy 
in patients < 12 years
Always with ICS — evidence A
Obstructive bronchitis 
— so-called early childhood asthma
Exacerbation of bronchoconstriction First-line treatment
Number of doses should be adjusted 
to the patient’s clinical condition
Stable COPD Initial treatment — dyspnoea attack 
or/and respiratory difficulties
As-needed SABA
— Only patients from group A
— Reduction in symptoms and an increase 
in FEV1 — evidence A
— Combination of SABA + SAMA 
is superior to SABA or SAMA alone 
(symptoms and FEV1) — evidence A
COPD — exacerbation Acute exacerbation of disease
SABA added to other medication
Increase the dose or frequency of SABA 
or combine SABA and SAMA in the initial 
treatment of acute exacerbation — evidence C
Bronchiolitis Selected cases with confirmed positive 
clinical response to treatment
In most cases there are no indications 
to routine therapy
Cystic fibrosis Pulmonary exacerbation with features 
of bronchoconstriction and confirmed 
positive clinical response or in patients 
with positive BDR test, before inhalation 
of hypertonic saline
Rather commonly used, however 
ecommendations are not explicit
Transient tachypnoea of the newborns Very poor evidences for the efficacy
Chronic lung disease in premature babies Prevention and treatment Poor evidences for the efficacy
Familial dysautonomia SABA + SAMA 1 study confirming SABA efficacy
Other diseases with reversible 
bronchoconstriction
Acute chest syndrome in sickle cell disease Further studies are needed
Bronchodilator reversibility (BDR) test Spirometric features of bronchoconstriction
(FEV1%FVC < 80 % predicted value, 
FEV1%VC < 80% predicted value, 
PEF < 80% predicted value)
2–4 puffs of salbutamol
pMDI + inhalation chamber as the standard 
of BDR test
*One shouldn’t be afraid of administration of SABA (salbutamol) in the elderly (> 90 years) [65] FEV1 — forced expiratory volume in the first second; ICS — inhaled 
corticosteroids; COPD — chronic obstructive pulmonary disease; SABA — short-acting b2-agonists; SAMA — short-acting muscarinic antagonists; SMART — Single 
Maintenance and Reliver Therapy
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6. Parenteral, oral, or nebulized SABA are as-
sociated with increased risk of side effects 
(tachycardia, muscle tremor, headaches, hy-
pokalaemia). In this respect inhalation from 
pMDI is the safest method [53, 54].
7. Short-acting b2-agonist (alternatively in com-
bination with ipratropium bromide) in pMDI 
+ IC or in nebulization is the first-line initial 
treatment of acute exacerbation of COPD [55]. 
Dose of SABA from pMDI: 1–2 puffs every 
hour for the first 2–3 hours of treatment, then 
1–2 puffs every 2–4 hours depending on the 
response to the treatment [56].
8. Patients with COPD should receive air-driv-
en nebulization of SABA, but not high-flow 
oxygen-driven nebulization to avoid hyper-
capnia in patients with chronic respiratory 
failure [57].
Indications to SABA
Short-acting b2-agonists have been very 
important drugs for many years used in the man-
agement of various bronchoconstrictive diseases 
in children and adults. Indications for their ad-
ministration were collected in Table 3. 
Current place of SABA in the management 
of asthma is defined by GINA 2019 report, which 
considerably changes former recommendations 
(tab. 4) [35]. Experts in this report do not recom-
mend SABA monotherapy in all age groups (look 
tab. 3) because of patient’s safety. Each SABA 
(regardless of its inhalation formulation) should 
be used simultaneously with ICS — from one or 
separate inhalers (or sometimes with oral/paren-
teral corticosteroid). 
GINA 2019 report based on high-quality clin-
ical studies recommends the following as-need-
ed (emergency) step 1–5 treatment in patient 
≥ 12 years: low dose ICS in combination with 
formoterol [36]. As-needed SABA from pMDI or 
DPI remains alternative option (worse regarding 
the efficacy and safety). In children 6–11 years 
preferred emergency management is administra-
tion of SABA from pMDI + inhalation chamber 
in combination with ICS (any medication) or 
oral corticosteroid [36]. Administration of SABA 
from pMDI + inhalation chamber: 4–10 puffs 
for every 20 minutes for the first hour of symp-
toms. Budesonide in combination with formoterol 
in SMART therapy model is alternative option for 
some children [36]. In group of children up to 
5 years the only option of emergency treatment 
is SABA „as-needed” — from pMDI + inhalation 
chamber (preferred management) or in nebuli-
zation (alternative management) in all asthma 
steps [36].
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